AbbVie and J&J's Imbruvica May Become Largest Cancer Drug Ever
2015-08-19 11:12:02.597 GMT
BI PHRM GLOB SBKEYS
AbbVie and Johnson & Johnson's blood cancer drug Imbruvica is
expected to achieve sales of $8.4 billion in 2020, based on
consensus, driven by its relatively high price. This exceeds the
$6.9 billion 2014 sales of Herceptin, the highest for a cancer
drug to date. Even as the field of immuno-oncology commands a
lot of air time, those drugs are only responsible for 36% of the
$48 billion increase in drug sales to $103.5 billion in 2020
from 2014. Pharma's targeted drugs remain the key drivers of
sales.
|0|0|565621|233860356|MMDL 233713096|MMDL 233713096|
This research note has been published by Bloomberg Intelligence.
For more information, see BI <GO>
-0- Aug/19/2015 11:12 GMT
2015-08-19 11:12:02.597 GMT
BI PHRM GLOB SBKEYS
AbbVie and Johnson & Johnson's blood cancer drug Imbruvica is
expected to achieve sales of $8.4 billion in 2020, based on
consensus, driven by its relatively high price. This exceeds the
$6.9 billion 2014 sales of Herceptin, the highest for a cancer
drug to date. Even as the field of immuno-oncology commands a
lot of air time, those drugs are only responsible for 36% of the
$48 billion increase in drug sales to $103.5 billion in 2020
from 2014. Pharma's targeted drugs remain the key drivers of
sales.
|0|0|565621|233860356|MMDL 233713096|MMDL 233713096|
This research note has been published by Bloomberg Intelligence.
For more information, see BI <GO>
-0- Aug/19/2015 11:12 GMT